Shanghai OPM Biosciences Co., Ltd. (SHA:688293)
China · Delayed Price · Currency is CNY 44.60
+1.63 (3.79%)
Mar 27, 2026, 4:00 PM EDT
Shanghai OPM Biosciences Revenue
In the year 2025, Shanghai OPM Biosciences had annual revenue of 354.91M CNY with 19.40% growth. Shanghai OPM Biosciences had revenue of 83.39M in the quarter ending December 31, 2025, with 2.46% growth.
Revenue
354.91M
Revenue Growth
+19.40%
P/S Ratio
16.34
Revenue / Employee
1.08M
Employees
64
Market Cap
5.80B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 354.91M | 57.67M | 19.40% |
| Dec 31, 2024 | 297.24M | 54.12M | 22.26% |
| Dec 31, 2023 | 243.12M | -51.24M | -17.41% |
| Dec 31, 2022 | 294.37M | 81.68M | 38.41% |
| Dec 31, 2021 | 212.68M | 87.71M | 70.19% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novogene | 2.17B |
| Kexing Biopharm | 1.54B |
| Xiangxue Pharmaceutical | 1.47B |
| Shenzhen Weiguang Biological Products | 1.14B |
| ChemPartner PharmaTech | 1.07B |
| Beijing Konruns Pharmaceutical | 871.31M |
| R&G PharmaStudies | 851.01M |
| GemPharmatech | 793.25M |